Sartorius Stedim Biotech shares break through their €228.40 resistance level, up 2.5%
The bioprocessing specialist accelerates mid-session in a Paris market that is slightly higher. The move places it in the upper part of the SBF 120 and above a technical threshold that the stock had approached several times in recent days.
A €228.40 level finally overcome, with €240 in sight
The stock gains 2.47% to €232.40, while the SBF 120 rises 0.35%. It ranks among the strongest gainers in the index.
During the session, the price broke above the highest level of the last 250 sessions, at €228.40, which has now become support. This level had been touched on November 12 before a 2% pullback, then approached on November 16 and 18, which gives today's move particular significance.
The next round-number marker is at €240. The RSI at 66 remains below the overbought zone, and the price stands 3.88% above the 20-day moving average, 8.39% above the 50-day moving average and 25.78% above the 200-day moving average. The stock is up 8.09% over one month and 28.75% over three months.
A stock priced at 46.7 times expected earnings, following confirmed nine-month results
According to the consensus of the analysts surveyed, the stock trades at about 46.7 times earnings for the current financial year and 38.4 times those of the following year. This valuation is supported by the first-nine-month accounts, published on October 22: operating activity rose 7.8% at constant exchange rates and annual targets were confirmed.
At the time of this publication, management cited the recurring activity linked to consumables as the backbone of the group, and strong growth in Asia-Pacific, at 10.6% at constant exchange rates, among the positive factors. It also listed among the risks the volatility of the sector and geopolitical uncertainties. The levels to watch remain the €228.40 support and the €240 mark.